4QK.DU Stock Analysis
4Q
Uncovered
Codexis Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 248 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and selling enzymes and other proteins. The firm commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.